uniQure Announces Presentations at Upcoming February Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 06, 2017 -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced presentations at the following conferences taking place in February:

Leerink Partners 6^th Annual Global Healthcare Conference, at the Lotte New York Palace Hotel in New York City  

• Matthew Kapusta, chief executive officer, will participate in a Fireside Chat on Wednesday, February 15^th at 3.00 p.m. EST. The live webcast can be accessed by the link displayed in the Investor section of the uniQure website at: http://uniqure.com/investors-newsroom/overview.php. The webcast replay will be available for at least 72 hours following the live event.

61^st Annual Meeting of Society of Thrombosis and Hemostatis Research at the Congress Center in Basel, Switzerland

• Professor Wolfgang Miesbach, M.D. professor of hematology at the University of Frankfurt, Germany and an investigator in the ongoing Phase 1-2 clinical trial of AMT-060 (AAV5 hFIX) gene transfer in adult patients with severe hemophilia B, will present previously disclosed interim results from the dose escalating study on Thursday, February 16^th at 15.00 CET/ 09.00 a.m. EST.

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com

uniQure Contacts:

Maria E. Cantor		
Direct: 339-970-7536	
Mobile:  617-680-9452	
[email protected] 	

Tom Malone
Direct:  339-970-7558
Mobile:  339-223-8541
[email protected]

Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79 
[email protected]